Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Wright's hip resurfacer finally approved by FDA

This article was originally published in Clinica

Executive Summary

The US FDA has granted premarket approval (PMA) for the Conserve Plus hip resurfacing system developed by Wright Medical after a wait of more than five years. The total surface arthroplasty system, a bone-conserving alternative to traditional total hip replacement, was submitted for FDA approval in early 2004. Arlington, Tennessee-based Wright will market Conserve Plus in the original femoral and acetabular component configuration specified in its PMA application. It will also work to introduce enhancements to the system, which are currently only available outside the US, via a PMA supplement. The US hip replacement market currently includes just two products, made by Smith & Nephew and Corin.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts